## **Special Issue**

# Cardiovascular Diseases and COVID-19

#### Message from the Guest Editors

At the outset of the COVID-19 pandemic, it immediately became apparent that individuals with previous cardiovascular diseases were at higher risk for severe forms of COVID-19 and adverse outcomes. Remarkably, recent studies have indicated that both symptomatic and asymptomatic SARS-CoV-2 infection has a negative impact on cardiovascular health and is associated with mortality during the period after COVID-19, which means that SARS-CoV-2 infection should be an important risk factor as well. This Special Issue welcomes original research articles and state-of-the-art reviews. Papers should provide novel data or gather current knowledge regarding the relationship between cardiovascular diseases and COVID-19, with a special focus on pathophysiological aspects of COVID-19 on cardiovascular health, covering (but not be limited to) molecular mechanisms that support deterioration processes such as inflammation, oxidative stress and endothelial dysfunction, useful clinical aspects related to cardiovascular diagnosis injuries, more accurate risk stratification, and finally therapeutic approaches in these specific circumstances.

#### **Guest Editors**

Dr. Aneta Aleksova

Deparment of Medical Surgical and Health Science, University of Trieste, Italy and Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), 34148 Trieste, Italy

Dr. Milijana Janjušević

Cardiothoracovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), Department of Medical Surgical and Health Science, University of Trieste, 34149 Trieste, Italy

#### Deadline for manuscript submissions

closed (28 February 2023)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/113627

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





### **About the Journal**

#### Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

#### Editor-in-Chief

#### Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

#### **Author Benefits**

#### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).